Form 4: Monopar COO's Stock Holdings Update Post-RSU Vesting

Monopar Therapeutics' COO, Andrew Cittadine, reported an increase in direct common stock ownership following RSU vesting and tax-related share disposition.

Summary

• Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics (MNPR), reported changes in his beneficial ownership of common stock and restricted stock units (RSUs).
• On December 31, 2025, Cittadine acquired 4,326 shares of Monopar Therapeutics common stock upon the vesting and settlement of restricted stock units.
• Concurrently, 1,889 shares of common stock were disposed of by the issuer at a price of $65.3 per share to cover applicable withholding taxes due upon the RSU vesting.
• Following these transactions, Cittadine directly beneficially owns 50,726 shares of Monopar Therapeutics common stock.
• Additionally, 4,326 derivative restricted stock units were disposed of (converted to common stock) on the same date.
• Cittadine now directly beneficially owns 48,267 derivative restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax withholding). These are expected events and do not inherently signal a positive or negative outlook for the company's performance or stock price.

Positives

• The vesting of restricted stock units indicates continued compensation and alignment of the Chief Operating Officer's interests with shareholders.
• The increase in direct common stock ownership (after accounting for tax withholding) reflects a net accumulation of company equity by a key executive.

Negatives

• A portion of the vested shares (1,889 shares) was withheld by the issuer to cover tax obligations, resulting in a reduction of the total shares received by the executive.

Future Outlook

The filing details future vesting schedules for outstanding restricted stock units, with full vesting dates extending to December 31, 2028, indicating continued long-term incentive compensation for the Chief Operating Officer.

Management Comments

• The filing details the acquisition of 4,326 shares of common stock by Chief Operating Officer Andrew Cittadine upon the vesting and settlement of restricted stock units.
• It also reports the disposition of 1,889 shares to satisfy tax withholding obligations related to the RSU vesting.

Industry Context

This Form 4 filing is a routine disclosure of an insider's stock transactions, specifically related to executive compensation through restricted stock units. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The reported transactions stem from the vesting of restricted stock units previously granted to Andrew Cittadine, the Chief Operating Officer, as part of his executive compensation package.
• The disposition of shares for tax withholding is a direct transaction between the company (issuer) and the executive (reporting person) to fulfill tax obligations arising from the RSU vesting.

Stakeholder Impact

• Shareholders: The filing indicates a routine change in an executive's direct ownership, which is generally not expected to have a significant immediate impact on the broader shareholder base.
• Employees: The RSU vesting and subsequent transactions are part of a standard executive compensation structure, which may be viewed as a normal course of business for employees.

Next Steps

• Future vesting of 3/48ths (813 shares) of the 2022 RSU grant every 3 months until fully vested on December 31, 2025 (completed with this filing).
• Future vesting of 3/48ths (978 shares) of the 2023 RSU grant every 3 months until fully vested on December 31, 2026.
• Future vesting of 3/48ths (2,536 shares) of the 2025 RSU grant every 3 months until fully vested on December 31, 2028.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions involving the vesting of restricted stock units and subsequent share disposition for tax purposes. Such events are expected as part of executive compensation and typically do not provide a strong signal for a 'buy' or 'sell' recommendation. The net change in direct ownership, while positive, is a result of pre-scheduled compensation rather than a discretionary open-market purchase or sale indicating a change in management's outlook. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information that would fundamentally alter an investment thesis.

Keywords

Monopar Therapeutics, MNPR, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Ownership, Andrew Cittadine